Procalcitonin in intensive care units: the PRORATA trial

The Lancet

Volumn 375, Issue 9726, 2010, Pages 1605-

  Tarnow Mordi, William ^a   Gebski, Val ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PROCALCITONIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; CALCITONIN; PROTEIN PRECURSOR;

CLINICAL TRIAL; DRUG EXPOSURE; DRUG USE; HUMAN; INFECTION; INTENSIVE CARE UNIT; LETTER; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT PLANNING; BACTERIAL INFECTION; BLOOD; NOTE;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; CALCITONIN; HUMANS; INTENSIVE CARE UNITS; PROTEIN PRECURSORS;

EID: 77951848165     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60695-2     Document Type: Letter

References (1)

1. Bouadma L., Luyt C.E., Tubach F., et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375 (2010) 463-474